tiprankstipranks
Advertisement
Advertisement

IRD Stock Latest News

Opus Genetics initiated with a Buy at TD Cowen
The FlyOpus Genetics initiated with a Buy at TD Cowen
3d ago
IRD
Opus Genetics: Buy Rating Reiterated as Analyst Sees Pivotal OPGx-BEST1 Data as Key Catalyst; $10 Price Target Unchanged
PremiumRatings
Opus Genetics: Buy Rating Reiterated as Analyst Sees Pivotal OPGx-BEST1 Data as Key Catalyst; $10 Price Target Unchanged
23d ago
IRD
Opus Genetics sets September timeline for retinal disease trial data
PremiumThe Fly
Opus Genetics sets September timeline for retinal disease trial data
23d ago
IRD
Yun Zhong Reiterates Buy on Opus Genetics as FDA-Backed, High-Power Phase 3 Design for OPGx-LCA5 Accelerates Path to Approval and Validates Broader Retinal Disease Pipeline
PremiumRatings
Yun Zhong Reiterates Buy on Opus Genetics as FDA-Backed, High-Power Phase 3 Design for OPGx-LCA5 Accelerates Path to Approval and Validates Broader Retinal Disease Pipeline
25d ago
IRD
Opus Genetics: FDA-Backed Phase 3 Path and Strong Early Efficacy Support Reiterated Buy on IRD with Unchanged $10 Price Target
PremiumRatings
Opus Genetics: FDA-Backed Phase 3 Path and Strong Early Efficacy Support Reiterated Buy on IRD with Unchanged $10 Price Target
26d ago
IRD
Opus Genetics FDA alignment further de-risks path to market, says Chardan
PremiumThe FlyOpus Genetics FDA alignment further de-risks path to market, says Chardan
26d ago
IRD
Morning Movers: TeraWulf surges following lease agreement with Anthropic
Premium
The Fly
Morning Movers: TeraWulf surges following lease agreement with Anthropic
26d ago
IRD
KOS
Opus Genetics announces FDA alignment on OPGx-LCA5 trial
Premium
The Fly
Opus Genetics announces FDA alignment on OPGx-LCA5 trial
26d ago
IRD
Opus Genetics Advances New Gene Therapy Trial for Rare Childhood Blindness
PremiumCompany Announcements
Opus Genetics Advances New Gene Therapy Trial for Rare Childhood Blindness
30d ago
IRD
Opus Genetics to join Russell 3000, Russell 2000 and Russell Microcap Indexes
PremiumThe Fly
Opus Genetics to join Russell 3000, Russell 2000 and Russell Microcap Indexes
1M ago
IRD
Buy Rating Reaffirmed as Clinical Promise Supports Risk‑Reward; $12 Price Target Maintained
PremiumRatings
Buy Rating Reaffirmed as Clinical Promise Supports Risk‑Reward; $12 Price Target Maintained
1M ago
IRD
Opus Genetics initiated with an Outperform at RBC Capital
PremiumThe Fly
Opus Genetics initiated with an Outperform at RBC Capital
1M ago
IRD
Opus Genetics assumed with a Buy at Chardan
PremiumThe FlyOpus Genetics assumed with a Buy at Chardan
1M ago
IRD
Analyst Reiterates Buy on Opus Genetics, Maintains $8 Price Target on Advancing Gene Therapy Pipeline
Premium
Ratings
Analyst Reiterates Buy on Opus Genetics, Maintains $8 Price Target on Advancing Gene Therapy Pipeline
1M ago
IRD
BTIG Reiterates Buy on Opus Genetics, Citing De-Risked IRD Pipeline and Maintaining $12 Price Target
Premium
Ratings
BTIG Reiterates Buy on Opus Genetics, Citing De-Risked IRD Pipeline and Maintaining $12 Price Target
1M ago
IRD
Opus Genetics Showcases Expanding Gene Therapy Pipeline Progress
PremiumCompany Announcements
Opus Genetics Showcases Expanding Gene Therapy Pipeline Progress
2M ago
8K
IRD
Opus Genetics Highlights Advancing Inherited Retinal Disease Pipeline
PremiumCompany Announcements
Opus Genetics Highlights Advancing Inherited Retinal Disease Pipeline
2M ago
8K
IRD
Opus Genetics management to meet with BTIG
PremiumThe Fly
Opus Genetics management to meet with BTIG
2M ago
IRD
Opus Genetics registers to sell 2.68M shares of common stock for holders
PremiumThe Fly
Opus Genetics registers to sell 2.68M shares of common stock for holders
2M ago
IRD
Opus Genetics initiated with a Buy at Guggenheim
PremiumThe FlyOpus Genetics initiated with a Buy at Guggenheim
2M ago
IRD
Opus Genetics management to meet with Citizens
Premium
The Fly
Opus Genetics management to meet with Citizens
2M ago
IRD
Opus Therapeutics: Buy Rating Reiterated on Advancing Gene Therapy Pipeline and Solid Cash Runway; $10 Price Target Maintained
Premium
Ratings
Opus Therapeutics: Buy Rating Reiterated on Advancing Gene Therapy Pipeline and Solid Cash Runway; $10 Price Target Maintained
2M ago
IRD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >